323 related articles for article (PubMed ID: 17347960)
1. [Calcimimetics, phosphate binders, vitamin D and its analogues for treating secondary hyperparathyroidism in chronic kidney disease: guideline from the Italian Society of Nephrology].
Mazzaferro S; Cozzolino M; Marangella M; Strippoli GF; Messa P;
G Ital Nefrol; 2007; 24 Suppl 37():S107-24. PubMed ID: 17347960
[TBL] [Abstract][Full Text] [Related]
2. Hyperparathyroidism in chronic kidney disease patients: an update on current pharmacotherapy.
Fukagawa M; Komaba H; Kakuta T
Expert Opin Pharmacother; 2013 May; 14(7):863-71. PubMed ID: 23521343
[TBL] [Abstract][Full Text] [Related]
3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
4. Controversies in the Management of Secondary Hyperparathyroidism in Chronic Kidney Disease.
Bellorin-Font E; Vasquez-Rios G; Martin KJ
Curr Osteoporos Rep; 2019 Oct; 17(5):333-342. PubMed ID: 31485996
[TBL] [Abstract][Full Text] [Related]
5. [Use of statins for preventing cardiovascular and renal outcomes in patients with chronic kidney disease excluding dialysis: guideline from the Italian Society of Nephrology].
De Nicola L; Strippoli GF; Ravani P; Del Vecchio L; Cianciaruso B;
G Ital Nefrol; 2007; 24 Suppl 37():S83-90. PubMed ID: 17347957
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
Joy MS; Karagiannis PC; Peyerl FW
J Manag Care Pharm; 2007 Jun; 13(5):397-411. PubMed ID: 17605511
[TBL] [Abstract][Full Text] [Related]
7. Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children.
Wesseling-Perry K; Salusky IB
Pediatr Nephrol; 2013 Apr; 28(4):617-25. PubMed ID: 23381010
[TBL] [Abstract][Full Text] [Related]
8. Advances in pharmacotherapy for secondary hyperparathyroidism.
Rodríguez M; Rodríguez-Ortiz ME
Expert Opin Pharmacother; 2015; 16(11):1703-16. PubMed ID: 26159447
[TBL] [Abstract][Full Text] [Related]
9. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
10. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
[TBL] [Abstract][Full Text] [Related]
11. [Haemoglobin targets for chronic kidney disease: guideline from the Italian Society of Nephrology].
Canavese C; Strippoli GF; Bonomini M; Triolo G;
G Ital Nefrol; 2007; 24 Suppl 37():S99-106. PubMed ID: 17347959
[TBL] [Abstract][Full Text] [Related]
12. [Antihypertensive agents for the prevention of chronic kidney disease progression: guideline from the Italian Society of Nephrology].
Del Vecchio L; Manno C; Ravani P; De Nicola L; Cianciaruso B;
G Ital Nefrol; 2007; 24 Suppl 37():S64-82. PubMed ID: 17347956
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of cinacalcet for the treatment of secondary hyperparathyroidism in patients with advanced chronic kidney disease before initiation of regular dialysis.
Montenegro J; Cornago I; Gallardo I; García-Ledesma P; Hernando A; Martinez I; Muñoz RI; Romero MA
Nephrology (Carlton); 2012 Jan; 17(1):26-31. PubMed ID: 22022934
[TBL] [Abstract][Full Text] [Related]
14. Relationship between reductions in parathyroid hormone and serum phosphorus during the management of secondary hyperparathyroidism with calcimimetics in hemodialysis patients.
Cooper K; Quarles D; Kubo Y; Tomlin H; Goodman W
Nephron Clin Pract; 2012; 121(3-4):c124-30. PubMed ID: 23208191
[TBL] [Abstract][Full Text] [Related]
15. [Erythropoietins and haemoglobin targets to prevent the progression of chronic kidney disease: guideline from the Italian Society of Nephrology].
Ravani P; Del Vecchio L; De Nicola L; Cianciaruso B;
G Ital Nefrol; 2007; 24 Suppl 37():S91-8. PubMed ID: 17347958
[TBL] [Abstract][Full Text] [Related]
16. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
17. Vitamin D, vitamin D receptor and the importance of its activation in patients with chronic kidney disease.
Bover J; Egido J; Fernández-Giráldez E; Praga M; Solozábal-Campos C; Torregrosa JV; Martínez-Castelao A
Nefrologia; 2015; 35(1):28-41. PubMed ID: 25611831
[TBL] [Abstract][Full Text] [Related]
18. [The use of Cinacalcet in chronic kidney disease: a case report].
Russo R; Argentino G; Maresca ID; Sannino G; Memoli A; Memoli B
G Ital Nefrol; 2015; 32(4):. PubMed ID: 26252263
[TBL] [Abstract][Full Text] [Related]
19. Challenges in the therapy of secondary hyperparathyroidism.
Wood C; González EA; Martin KJ
Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism.
Ureña-Torres P; Bridges I; Christiano C; Cournoyer SH; Cooper K; Farouk M; Kopyt NP; Rodriguez M; Zehnder D; Covic A
Nephrol Dial Transplant; 2013 May; 28(5):1241-54. PubMed ID: 23328710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
